Sol-Gel Technologies Ltd. (FRA:4SG)

Market Cap	210.67M +1,149.6%
Revenue (ttm)	16.01M +52.6%
Net Income	-907.20K
EPS	-0.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	60.00
Previous Close	64.00
Day's Range	60.00 - 60.00
52-Week Range	5.75 - 82.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 28
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4SG

Financial Performance

In 2025, Sol-Gel Technologies's revenue was $19.39 million, an increase of 68.04% compared to the previous year's $11.54 million. Losses were -$6.13 million, -42.09% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error